↓ Skip to main content

Fluid biomarkers in Alzheimer’s disease – current concepts

Overview of attention for article published in Molecular Neurodegeneration, January 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)

Mentioned by

twitter
4 tweeters
patent
1 patent
facebook
3 Facebook pages
reddit
2 Redditors

Readers on

mendeley
333 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fluid biomarkers in Alzheimer’s disease – current concepts
Published in
Molecular Neurodegeneration, January 2013
DOI 10.1186/1750-1326-8-20
Pubmed ID
Authors

Christoffer Rosén, Oskar Hansson, Kaj Blennow, Henrik Zetterberg

Abstract

The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain imaging and cerebrospinal fluid (CSF) biomarkers, with the aim of increasing the certainty of whether a patient has an ongoing AD neuropathologic process or not. The CSF biomarkers total tau (T-tau), hyperphosphorylated tau (P-tau) and the 42 amino acid isoform of amyloid β (Aβ42) reflect the core pathologic features of AD, which are neuronal loss, intracellular neurofibrillary tangles and extracellular senile plaques. Since the pathologic processes of AD start decades before the first symptoms, these biomarkers may provide means of early disease detection. The updated guidelines identify three different stages of AD: preclinical AD, mild cognitive impairment (MCI) due to AD and AD with dementia. In this review, we aim to summarize the CSF biomarker data available for each of these stages. We also review results from blood biomarker studies. In summary, the core AD CSF biomarkers have high diagnostic accuracy both for AD with dementia and to predict incipient AD (MCI due to AD). Longitudinal studies on healthy elderly and recent cross-sectional studies on patients with dominantly inherited AD mutations have also found biomarker changes in cognitively normal at-risk individuals. This will be important if disease-modifying treatment becomes available, given that treatment will probably be most effective early in the disease. An important prerequisite for this is trustworthy analyses. Since measurements vary between studies and laboratories, standardization of analytical as well as pre-analytical procedures will be essential. This process is already initiated. Apart from filling diagnostic roles, biomarkers may also be utilized for prognosis, disease progression, development of new treatments, monitoring treatment effects and for increasing the knowledge about pathologic processes coupled to the disease. Hence, the search for new biomarkers continues. Several candidate biomarkers have been found in CSF, and although biomarkers in blood have been harder to find, some recent studies have presented encouraging results. But before drawing any major conclusions, these results need to be verified in independent studies.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 333 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 3 <1%
United States 2 <1%
Spain 2 <1%
Brazil 2 <1%
India 1 <1%
South Africa 1 <1%
Czechia 1 <1%
United Kingdom 1 <1%
Mexico 1 <1%
Other 3 <1%
Unknown 316 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 71 21%
Researcher 62 19%
Student > Master 51 15%
Student > Bachelor 38 11%
Student > Postgraduate 20 6%
Other 56 17%
Unknown 35 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 91 27%
Medicine and Dentistry 60 18%
Neuroscience 34 10%
Biochemistry, Genetics and Molecular Biology 30 9%
Chemistry 16 5%
Other 47 14%
Unknown 55 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2016.
All research outputs
#3,796,446
of 19,802,760 outputs
Outputs from Molecular Neurodegeneration
#429
of 754 outputs
Outputs of similar age
#32,879
of 170,488 outputs
Outputs of similar age from Molecular Neurodegeneration
#1
of 1 outputs
Altmetric has tracked 19,802,760 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 754 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 170,488 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them